Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
AssigneeMemorial Sloan Kettering Cancer Center
InventorsRaymond P. Warrell, Jr., Pier Paolo Pandolfi, Janice L. Gabrilove
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Claims7
A method of treating acute myelogenous leukemia in a human comprising administering to a human having acute myelogenous leukemia a therapeutically effective amount of arsenic trioxide, wherein the acute myelogenous leukemia is selected from the group consisting of acute myeloblastic leukemia, acute monoblastic leukemia, acute erythroleukemic leukemia, acute megakaryoblastic leukemia, acute myelomonocytic leukemia, or acute undifferentiated leukemia.
A method for treating chronic myelogenous leukemia in a human comprising administering to a human with chronic myelogenous leukemia a therapeutically effective amount of arsenic trioxide.
A method for treating acute myelogenous leukemia or chronic myelogenous leukemia in a human who is resistant to treatment with retinoids comprising administering to the human a therapeutically effective amount of arsenic trioxide, wherein the acute myelogenous leukemia is selected from the group consisting of acute myeloblastic leukemia, acute monoblastic leukemia, acute erythroleukemic leukemia, acute megakaryoblastic leukemia, acute myelomonocytic leukemia, or acute undifferentiated leukemia.
Dependencies are inferred from the claim text.